BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $19.50 Consensus Price Target from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $19.50.

BCRX has been the topic of several recent research reports. Needham & Company LLC cut their target price on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Citizens Jmp lowered their price objective on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, December 29th. JMP Securities boosted their target price on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a report on Wednesday, October 15th. Finally, Barclays lowered their price target on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 4th.

BioCryst Pharmaceuticals Stock Down 2.9%

BCRX stock opened at $7.40 on Thursday. The company has a 50 day moving average of $7.35 and a two-hundred day moving average of $7.82. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -148.00, a PEG ratio of 0.47 and a beta of 0.80. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The company had revenue of $159.40 million during the quarter, compared to analyst estimates of $162.91 million. During the same period last year, the company posted ($0.07) earnings per share. The company’s revenue was up 36.1% compared to the same quarter last year. On average, research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Insider Activity

In related news, insider Alane P. Barnes sold 21,773 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.65, for a total value of $166,563.45. Following the transaction, the insider directly owned 398,751 shares in the company, valued at approximately $3,050,445.15. This trade represents a 5.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 183,453 shares of company stock worth $1,330,965. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of BioCryst Pharmaceuticals by 7.7% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 1,288 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 1,458 shares in the last quarter. Captrust Financial Advisors increased its holdings in shares of BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 1,527 shares in the last quarter. Main Management ETF Advisors LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company’s stock valued at $1,005,000 after purchasing an additional 1,824 shares in the last quarter. Finally, Creative Planning grew its position in shares of BioCryst Pharmaceuticals by 2.6% in the 3rd quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock valued at $672,000 after purchasing an additional 2,280 shares during the period. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.